Japan Tobacco Inc.

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

LEO Pharma A/S may have suffered a setback in the clinic this summer, with a rare skin disease drug failing in Phase III, but the Danish dermatology specialist has enjoyed a strong first half of 2024

LEO Pharma is poised to gain a first approval for Anzupgo, a new topical treatment for moderate to severe chronic hand eczema (CHE) that is set to become a major earner for the Denmark-headquartered

With its drawn-out acquisition of Timber Pharmaceuticals, Inc. finally signed off, LEO Pharma A/S can now turn its attention to other potential deals that will cement its place as a leading player